NRIX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 105154 min ago

@ $9.02

Išleistas: 14 vas. 2024 @ 21:04

Grąža: 37.03%

Ankstesnis signalas: vas. 14 - 16:30

Ankstesnis signalas: Pardavimas

Grąža: 0.89 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders...

Stats
Šios dienos apimtis	599 462
Vidutinė apimtis	1.02M
Rinkos kapitalizacija	733.16M
EPS	$0 ( 2024-04-11 )
Kita pelno data	( $-0.720 ) 2024-07-11
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.65
ATR14	$0.0200 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-16	Van Houte Hans	Sell	6 812	Common Stock
2024-02-13	Van Houte Hans	Buy	150 000	Employee Stock Option (right to buy)
2024-02-13	Van Houte Hans	Buy	45 000	Restricted Stock Units
2024-02-13	Ring Christine	Buy	150 000	Employee Stock Option (right to buy)
2024-02-13	Ring Christine	Buy	45 000	Restricted Stock Units

INSIDER POWER
91.86
Last 100 transactions
Buy: 2 499 418 \| Sell: 108 263

Tūris Koreliacija

Ilgas: -0.44 (neutral)

Trumpas: 0.37 (neutral)

Signal:(51.965) Neutral

Nurix Therapeutics, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Nurix Therapeutics, Inc. Koreliacija - Valiuta/Žaliavos

-0.17
( neutral )

-0.20
( neutral )

0.00
( neutral )

-0.36
( neutral )

-0.10
( neutral )

-0.06
( neutral )

Nurix Therapeutics, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$76.99M
Bruto pelnas:	$63.33M (82.26 %)
EPS:	$-2.65

FY	2023
Pajamos:	$76.99M
Bruto pelnas:	$63.33M (82.26 %)
EPS:	$-2.65

FY	2022
Pajamos:	$38.63M
Bruto pelnas:	$27.82M (72.02 %)
EPS:	$-3.42

FY	2021
Pajamos:	$29.75M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.64

Financial Reports:

No articles found.

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.